FiscalNote Holdings, Inc. (NOTE)

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	115.67	120.27	132.65	113.77	82.91	65.16
Revenue Growth (YoY)	-13.18%	-9.33%	16.60%	37.21%	27.25%	-1.08%
Cost of Revenue	25.38	25.64	40.25	31.94	21.8	12.62
Gross Profit	90.29	94.63	92.39	81.83	61.11	52.54
Selling, General & Admin	102.52	103.82	129.14	136.44	78.62	56.38
Research & Development	12.45	12.83	18.19	20.74	24.02	15.12
Operating Expenses	124.55	126.57	158.84	167.62	111.99	78.85
Operating Income	-34.26	-31.95	-66.44	-85.79	-50.88	-26.31
Interest Expense	-21.35	-23.59	-29.94	-95.74	-64.8	-31.83
Earnings From Equity Investments	-	-	-	-	-	-0.08
Other Non Operating Income (Expenses)	-5.03	-6.43	15.92	11.7	3.07	8.17
EBT Excluding Unusual Items	-60.64	-61.97	-80.47	-169.83	-112.61	-50.05
Merger & Restructuring Charges	-	0	0.77	-2.4	-4.7	-0.22
Impairment of Goodwill	-	-	-25.84	-	-	-
Gain (Loss) on Sale of Assets	16.16	72.02	-	-	-	-
Asset Writedown	-	-	-6.22	-	-	-
Other Unusual Items	-1.78	-	-3.47	-49.28	-	-2.43
Pretax Income	-46.26	10.05	-115.24	-221.51	-117.31	-52.71
Income Tax Expense	-0.93	0.54	0.22	-3.25	-7.89	-1.44
Net Income	-45.33	9.52	-115.46	-218.26	-109.42	-51.27
Preferred Dividends & Other Adjustments	-	-	-	26.57	197.51	31.99
Net Income to Common	-45.33	9.52	-115.46	-244.83	-306.93	-83.26
Shares Outstanding (Basic)	142	137	131	67	16	10
Shares Outstanding (Diluted)	142	137	131	67	16	10
Shares Change (YoY)	8.88%	4.47%	97.55%	329.01%	62.82%	4.23%
EPS (Basic)	-0.32	0.07	-0.88	-3.68	-19.80	-8.74
EPS (Diluted)	-0.35	0.07	-0.88	-3.68	-19.80	-8.74
Free Cash Flow	-13.93	-14.18	-43.43	-83.99	-42.62	-21.33
Free Cash Flow Per Share	-0.10	-0.10	-0.33	-1.26	-2.75	-2.24
Gross Margin	78.06%	78.68%	69.66%	71.93%	73.70%	80.63%
Operating Margin	-29.62%	-26.56%	-50.09%	-75.41%	-61.37%	-40.38%
Profit Margin	-39.19%	7.91%	-87.04%	-215.20%	-370.19%	-127.79%
Free Cash Flow Margin	-12.04%	-11.79%	-32.74%	-73.83%	-51.40%	-32.74%
EBITDA	-23.5	-20.78	-53.59	-74.11	-40.35	-17.86
EBITDA Margin	-20.31%	-17.28%	-40.40%	-65.14%	-48.66%	-27.41%
D&A For EBITDA	10.76	11.17	12.86	11.69	10.54	8.45
EBIT	-34.26	-31.95	-66.44	-85.79	-50.88	-26.31
EBIT Margin	-29.62%	-26.56%	-50.09%	-75.41%	-61.37%	-40.38%
Effective Tax Rate	-	5.33%	-	-	-	-
Revenue as Reported	115.67	120.27	132.65	113.77	82.91	65.16

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q